Patents Examined by Zachary J Miknis
  • Method for treating cancer
    Patent number: 11395845
    Abstract: The present disclosure relates to a method of treating prostate cancer comprising administering to a subject in need thereof a therapeutically effective amount of a vasopressin analogue.
    Type: Grant
    Filed: August 24, 2020
    Date of Patent: July 26, 2022
    Assignee: SUNNYBROOK RESEARCH INSTITUTE
    Inventors: Laurence H. Klotz, Vasundara Venkateswaran
  • Collagen peptide-based medicament compositions and devices and methods of production and use thereof
    Patent number: 11389513
    Abstract: The present invention is in the fields of medicinal chemistry, biotechnology and pharmaceuticals. The invention provides compositions comprising one or more collagen mimetic peptides, optionally attached to one or more therapeutic compounds or one or more imaging compounds, for use in methods of treating, preventing, ameliorating, curing and diagnosing certain diseases and physical disorders in humans and veterinary animals, particularly anterior and posterior segment ocular diseases and physical disorders, paraocular and extraocular diseases and physical disorders, and nerve or nervous system diseases and physical disorders, as well as methods of manufacturing such compositions. The invention also provides medical devices comprising one or more such compositions of the invention.
    Type: Grant
    Filed: April 22, 2020
    Date of Patent: July 19, 2022
    Assignee: SUSTAIN HOLDINGS, LLC
    Inventors: Richard E. Schlumpf, Robert Baratta, Shawn Delorey, David J. Calkins
  • Amino acid-specific binder and selectively identifying an amino acid
    Patent number: 11390653
    Abstract: An amino acid-specific binder selectively binds to a binding amino acid. A binder complex selectively identifies the binding amino acid and includes an adjunct attached to the amino acid-specific binder. The adjunct includes a taggant, protein, substrate, or chemical modifier. Selectively identifying an N-terminal amino acid includes anchoring a C-terminal end; contacting an N-terminal amino acid of the anchored analyte with the binder complex; selectively binding when the N-terminal amino acid includes the binding amino acid; producing, by the taggant of the tagged complex, a taggant signal; detecting the taggant signal; and identifying the N-terminal amino acid based on the taggant signal.
    Type: Grant
    Filed: August 6, 2020
    Date of Patent: July 19, 2022
    Assignee: GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF COMMERCE
    Inventors: Jennifer A. Tullman, Zvi Kelman, John P. Marino
  • Methods and compositions for the prevention and treatment of disease
    Patent number: 11376304
    Abstract: The present technology is directed to compositions and methods for preventing, ameliorating, or reducing the severity of one or more signs, or symptoms associated with a reduction of function, decreased expression level of, and/or deficiency in one or more of COL4A3, COL4A4 and COL4A5 genes. Also disclosed herein are methods of preventing or treating Alport Syndrome in a mammalian subject, reducing risk factors associated with Alport Syndrome, and/or reducing the likelihood or severity of Alport Syndrome. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide.
    Type: Grant
    Filed: August 17, 2020
    Date of Patent: July 5, 2022
    Assignee: STEALTH BIOTHERAPEUTICS INC.
    Inventor: D. Travis Wilson
  • Efficient delivery of therapeutic molecules to cells of the inner ear
    Patent number: 11370823
    Abstract: Compositions and provided to induce cells of the inner ear to renter the cell cycle and to proliferate. In particular, hair cells are induced to proliferate by administration of a composition which activates the Myc and Notch. Supporting cells are induced to transdifferentiate to hair cells by inhibition of Myc and Notch activity or the activation of Atoh1. Methods of treatment include the intracellular delivery of these molecules to a specific therapeutic target.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: June 28, 2022
    Assignees: Massachusetts Eye and Ear Infirmary, President and Fellows of Harvard College
    Inventors: Zheng-Yi Chen, David R. Liu, Margie Li, David B. Thompson, John Zuris
  • C1-INH compositions and methods for the prevention and treatment of disorders associated with C1 esterase inhibitor deficiency
    Patent number: 11364288
    Abstract: Compositions and methods for the treatment and/or prevention of disorders associated with C1 esterase inhibitor deficiency are disclosed.
    Type: Grant
    Filed: October 2, 2019
    Date of Patent: June 21, 2022
    Assignee: VIROPHARMA BIOLOGICS LLC
    Inventors: Stephen Ruddy, Mark Cornell Manning, Ryan Erik Holcomb
  • Prohemostatic proteins for the treatment of bleeding
    Patent number: 11357836
    Abstract: This disclosure relates to recombinant FXa polypeptides that can be used as antidotes to completely or partially reverse an anti-coagulant effect of a coagulation inhibitor in a subject, preferably a direct factor Xa inhibitor. Disclosed herein are recombinant factor Xa proteins and a method of completely or partially reversing an anti-coagulant effect of a coagulation inhibitor in a subject.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: June 14, 2022
    Assignee: Academisch Ziekenhuis Leiden
    Inventors: Daniël Verhoef, Pieter H. Reitsma, Mettine H. A. Bos
  • Methods for the iodination of biomolecules
    Patent number: 11358982
    Abstract: Provided herein are methods for iodinating biomolecules, including proteins and peptides. The methods can be used to successfully and efficiently iodinate biomolecules under relatively mild reaction conditions. As a consequence, the methods described herein can be used to iodinate biomolecules that include, for example, an oxidatively unstable moiety (e.g., an optical dye) without adversely impacting the oxidatively unstable moiety.
    Type: Grant
    Filed: November 1, 2017
    Date of Patent: June 14, 2022
    Assignee: Ohio State Innovation Foundation
    Inventor: Krishan Kumar
  • PI3K gamma inhibitor peptide for treatment of respiratory system diseases
    Patent number: 11352400
    Abstract: Fusion peptide comprising: i) an amino acid sequence as defined in SEQ ID No.: 1 or a related homolog having at least 90% identity with SEQ ID No.: 1 and having the ability of the sequence SEQ ID No.: 1 to inhibit the kinase-independent function of PI3K?, and ii) a peptide having the ability to penetrate a cell.
    Type: Grant
    Filed: June 25, 2020
    Date of Patent: June 7, 2022
    Assignee: KITHER BIOTECH SRL
    Inventors: Emilio Hirsch, Alessandra Ghigo
  • Antimicrobial agents and their use in therapy
    Patent number: 11337427
    Abstract: The present invention provides an agent, or a composition containing an agent, for use in treating or preventing a bacterial infection in a subject, wherein said agent comprises: (i) an oligopeptidic compound comprising a PCNA interacting motif and a domain that facilitates the cellular uptake of said compound, wherein the PCNA interacting motif is X1X2X3X4X5 (SEQ ID NO: 1) and wherein: X1 is a basic amino acid; X2 is an aromatic amino acid; X3 is an uncharged amino acid other than an aromatic amino acid, Glycine (G) and Proline (P); X4 is any amino acid other than Proline (P), an acidic amino acid or an aromatic amino acid; and X5 is a basic amino acid or Proline (P); or (ii) a nucleic acid molecule comprising a sequence encoding the oligopeptidic compound of (i). In certain aspects the agent and compositions of the invention may be used as single agents.
    Type: Grant
    Filed: October 3, 2019
    Date of Patent: May 24, 2022
    Assignee: Norwegian University of Science and Technology
    Inventors: Marit Otterlei, Siri Bachke
  • Stapled and stitched polypeptides and uses thereof
    Patent number: 11332496
    Abstract: The present invention provides stapled polypeptides of the Formulae (I) and (VI): and salts thereof; wherein the groups ; R1a, R1b, R1c, R2a, R3a, R2b, R3b, R4a, R4b, RA, RZ, L1a, L1b, L2, L3, XAA, v, w, p, m, s, n, t, and q are as defined herein. The present invention further provides methods of preparing the inventive stapled polypeptides from unstapled polypeptide precursors. The present invention further provides pharmaceutical compositions comprising a stapled polypeptide of Formula (I) or (VI), and methods of using the stapled peptides. The present invention also provides modifications of the staples post ring closing metathesis.
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: May 17, 2022
    Assignee: President and Fellows of Harvard College
    Inventors: Gregory L. Verdine, Gerard Hilinski
  • protein extract and uses thereof
    Patent number: 11319352
    Abstract: Methods of treating inflammation, in particular obesity, inducing satiation, prolonging satiety, and stimulating weight loss in a subject in need thereof, including the administration of a Brassicaceae protein extract. The Brassicaceae protein extract may be administered in the form of a dietary supplement or a food composition, either of which may include at least one additional ingredient.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: May 3, 2022
    Assignees: TARGEDYS, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ DE ROUEN
    Inventors: Serguei Fetissov, Grégory Lambert, Romain Legrand, Nicolas Lucas
  • Anti-angiogenic treatment with a combination of antagonists
    Patent number: 11318184
    Abstract: The teachings provided herein generally relate to a combination therapy and are directed to pharmaceutical compositions and methods for administering a combination of an ?5?1 antagonist with an ?2?1 antagonist to a subject. The methods are for use in inhibiting, preventing, or reversing angiogenesis, as well as in treating cancer. In some embodiments, the compositions and methods include a combined administration of VLO4 and VP12 (ECL12).
    Type: Grant
    Filed: June 12, 2020
    Date of Patent: May 3, 2022
    Assignee: CALIFORNIA NORTHSTATE COLLEGE OF PHARMACY, LLC
    Inventor: Xiaodong Feng
  • 3D synthetic tissue hydrogels
    Patent number: 11312950
    Abstract: A method to prepare synthetic hydrogels having tissue-specific properties, and a hydrogel comprising a polymer matrix comprising a plurality of peptide, are provided.
    Type: Grant
    Filed: February 13, 2018
    Date of Patent: April 26, 2022
    Assignee: University of Massachusetts
    Inventors: Lauren Jansen, Shelly Peyton
  • Prohemostatic proteins for the treatment of bleeding
    Patent number: 11304995
    Abstract: This disclosure relates to recombinant FXa polypeptides that can be used as antidotes to completely or partially reverse an anti-coagulant effect of a coagulation inhibitor in a subject, preferably a direct factor Xa inhibitor. Disclosed herein are recombinant factor Xa proteins and a method of completely or partially reversing an anti-coagulant effect of a coagulation inhibitor in a subject.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: April 19, 2022
    Assignee: Academisch Ziekenhuis Leiden
    Inventors: Daniël Verhoef, Pieter H. Reitsma, Mettine H. A. Bos
  • Anti-VEGF protein compositions and methods for producing the same
    Patent number: 11306135
    Abstract: The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.
    Type: Grant
    Filed: August 30, 2021
    Date of Patent: April 19, 2022
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Shunhai Wang, Ning Li, Hunter Chen, Amardeep Singh Bhupender Bhalla
  • Purification of factor VIII subspecies
    Patent number: 11299533
    Abstract: The present invention relates to a method for purifying a Factor VIII (FVIII) subspecies from a composition comprising FVIII, said method comprising an anion exchange chromatography step, a size exclusion chromatography step, and a concentration step. The invention also relates to a composition comprising a purified FVIII subspecies.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: April 12, 2022
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Meinhard Hasslacher, Martin Feichtinger, Philipp M. Bärnthaler, Christa Mayer, Birgit Reipert, Mantas Malisauskas, Julia Anzengruber
  • Protein conjugates
    Patent number: 11292825
    Abstract: The invention relates to protein conjugates and in particular conjugates of more than two protein or polypeptides. The compounds include a trivalent linker moiety that enables efficient production of desired products.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: April 5, 2022
    Assignee: Novo Nordisk A/S
    Inventors: Emiliano Clo, Mikael Kofod-Hansen, Henrik Sune Ramirez-Andersen, Nils Langeland Johansen
  • Pharmaceutical compound
    Patent number: 11286288
    Abstract: The present invention relates to compounds comprising a quaternary ammonium group, their use in skin diseases, and their preparation.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: March 29, 2022
    Assignee: VALLAURIX PTE. LTD.
    Inventors: Philippe Wolgen, Roland Callens
  • Treatment of age-related macular degeneration
    Patent number: 11273199
    Abstract: The present invention relates to a method and compositions for the treatment of age-related macular degeneration (AMD), in particular dry-AMD, specifically geographic atrophy (GA) or advanced dry-AMD. Specifically, the invention relates to an inner-blood-retinal-barrier (iBRB) or blood-brain-barrier (BBB) tight junction protein and/or a circadian clock protein for use in the prevention and/or treatment of age-related macular degeneration.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: March 15, 2022
    Assignee: The Provost, Fellows, Foundation Scholars & The Other Members Of Board, of he College of the Holy & Undiv. Trinity of Queen El
    Inventors: Matthew Campbell, Sarah Doyle, Natalie Hudson, Lucia Clekova